Jack D. Schwager, a seasoned trader and author, once aptly noted, "There are a million ways to make money in the markets, but the irony is that they are all very difficult to find." Despite the inherent challenges inherent in navigating financial markets, astute investors succeed in identifying promising stocks that can yield significant returns.
The following compilation highlights several healthcare stocks featured on our website that reached new 52-week high levels on Friday, July 12, 2024.
### Mirum Pharmaceuticals Inc. (MIRM)
Mirum is a commercial-stage biopharmaceutical company focusing on treatments for rare diseases. It currently markets three approved medications: Livmarli oral solution, Cholbam capsules, and Chenodal tablets.
For the full year 2024, Mirum anticipates reporting revenue between $310 million and $320 million, up from $186 million last year.
Recently, Mirum submitted a new drug application for Chenodol (Chenodiol tablets) aimed at treating Cerebrotendinous xanthomatosis. If approved, Chenodol will be the first and only medication approved for patients with this rare inborn bile acid metabolism disorder. Chenodol is already approved for radiolucent stones in the gallbladder.
Previously featured on our site on May 22, 2024, when it was trading at $25.81, MIRM closed Friday's trading session at $39.44, realizing a gain of nearly 53% in less than two months.
### Nurix Therapeutics Inc. (NRIX)
Nurix is a clinical-stage biopharmaceutical company specializing in targeted protein modulation drugs for hematologic malignancies and solid tumors.
The company’s lead drug candidate, NX-5948, is currently undergoing a phase 1a/b clinical trial in adults with relapsed or refractory B-cell malignancies, including CLL and non-Hodgkin lymphoma. Recent data from the phase Ia dose escalation part for patients with relapsed or refractory CLL showed an objective response rate of 69.2%. Further clinical data for CLL and NHL patients are expected in the latter half of 2024.
Additionally, Nurix's pipeline includes NX-2127, under phase 1a/b clinical trial for relapsed or refractory B-cell malignancies, and NX-1607, in a phase I trial for multiple oncology indications, both as a monotherapy and in combination with paclitaxel.
NRIX, originally featured on our site on July 11, 2023, when trading at $10.03, closed Friday's trading at $23.82, representing a gain of over 130%.
### The Pennant Group Inc. (PNTG)
Pennant is a holding company with subsidiaries that offer healthcare services through home health and hospice agencies, as well as senior living communities.
For the first quarter ending March 31, 2024, the company reported total revenue of $156.9 million, a 24.1% increase over the prior year quarter, and an adjusted net income of $6.0 million, marking a 55.0% increase.
Featured on our site on February 7, 2023, when it was trading at $12.38, PNTG closed Friday's trading at $25.62, reflecting a gain of over 100%.
### Amneal Pharmaceuticals Inc. (AMRX)
Amneal is a global pharmaceutical company with a diverse portfolio that includes retail generics, injectables, biosimilars, and specialty branded pharmaceuticals.
For the first quarter ending March 31, 2024, the company reported net revenue of $659 million, an 18% increase from $558 million in the first quarter of 2023.
Amneal is slated to release its second-quarter financial results for 2024 on August 9, 2024.
Initially featured on our site on June 11, 2024, when trading at $6.80, AMRX closed Friday's trading at $7.19, reflecting a gain of 6% over one month.
### AnaptysBio Inc. (ANAB)
AnaptysBio is a clinical-stage biotechnology company developing innovative immunology therapeutics.
A global phase 2b trial for ANB032 to treat atopic dermatitis is ongoing, with top-line data anticipated by year-end 2024. The company is also conducting global phase 2b and phase 2 trials for Rosnilimab in treating rheumatoid arthritis and ulcerative colitis, with top-line data expected by mid-2025 and the first half of 2026, respectively.
Featured on our site on October 5, 2023, when trading at $18.53, ANAB closed Friday's trading at $30.10, reflecting a gain of 62%.
### ADMA Biologics Inc. (ADMA)
ADMA is a fully-integrated commercial biopharmaceutical company focused on manufacturing and marketing specialty biologics for the treatment of immunodeficient patients and those at risk for certain infectious diseases.The company's marketed products include FDA-approved ASCENIV, BIVIGAM, and NABI-HB.
For 2024, the company anticipates total revenue exceeding $355 million and net income surpassing $85 million. Looking ahead to 2025, total revenue is projected to exceed $410 million, with net income surpassing $135 million.
We spotlighted ADMA on our site on February 15, 2024, when it was trading around $5.36. The stock closed Friday's trading at $12.78, reflecting a gain of over 130% in just 5 months.
**Krystal Biotech Inc. (KRYS)**
Krystal Biotech is a commercial-stage biotechnology firm focused on developing genetic medicines for unmet medical needs. Its leading product, VYJUVEK, was approved in the U.S. in May 2023 for the treatment of dystrophic epidermolysis bullosa.
VYJUVEK generated net product revenue of $45.3 million in the first quarter of 2024.
A phase I trial, PEARL-1, is currently evaluating KB301, which aims to address and potentially reverse biological changes in aging skin. Results from Cohort 3, focusing on the improvement of lateral canthal lines at rest, and Cohort 4, targeting dynamic wrinkles of the décolleté, are anticipated by mid-2024.
We featured KRYS on our site on June 8, 2023, when it was trading around $127.46. The stock closed Friday's trading at $203.13, representing a gain of 59% from our highlighted price.
**Select Medical Holdings Corp. (SEM)**
Select Medical operates critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States.
The company is scheduled to report its second-quarter financial results for the period ending June 30, 2024, on August 1, 2024, after market close. For the second quarter ending June 30, 2023, the company reported revenue of $1,674.5 million, an increase of 5.7% compared to the same quarter in the prior year.
We spotlighted SEM on our site on November 22, 2023, when it was trading around $23.36. The stock closed Friday's trading at $37.49, showing a gain of 60% in 8 months.
**Harrow Inc. (HROW)**
Harrow is a pharmaceutical company specializing in eyecare products for ophthalmic surgeries in the U.S., as well as medications for managing chronic and acute eye conditions.
For the first quarter ending March 31, 2024, Harrow reported revenue of $34.6 million, up 33% from $26.1 million in the same quarter the previous year. The company is confident in meeting its 2024 revenue guidance of more than $180 million, significantly up from $130.2 million last year.
We featured HROW on our site on February 13, 2024, when it was trading around $11.32. The stock closed Friday's trading at $23.61, indicating a gain of over 100% in just 5 months.
**Crinetics Pharmaceuticals Inc. (CRNX)**
Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company developing novel therapeutics for endocrine diseases and endocrine-related tumors.
Its lead drug candidate, Paltusotine, is being developed for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. A New Drug Application (NDA) for Paltusotine is expected to be submitted to the FDA for the treatment of acromegaly in the second half of 2024. Additionally, a phase III program for carcinoid syndrome is planned to begin by the end of 2024, pending discussions with the FDA.
We highlighted CRNX on our site on January 4, 2023, when it was trading around $18.17. The stock closed Friday's trading at $53.67, reflecting a gain of 195% from our featured price.
**Innoviva Inc. (INVA)**
Innoviva is a diversified holding company with a portfolio of royalties and other healthcare assets.
The company's royalty portfolio includes respiratory assets in partnership with Glaxo Group Limited, such as RELVAR/BREO ELLIPTA and ANORO ELLIPTA. Its commercial products include GIAPREZA, approved in the U.S. to increase blood pressure in adults with septic or other distributive shock, and XERAVA, approved for treating complicated intra-abdominal infections in adults.
For the first quarter of 2024, gross royalty revenue from Glaxo Group was $61.9 million compared to $60.3 million in the first quarter of 2023. Net product sales and license revenue were $19.1 million, a 66% increase from $11.5 million in the previous year.
We spotlighted INVA on our site on April 19, 2023, when it was trading around $11.34. The stock closed Friday's trading at $16.73, indicating a gain of 47% from our highlighted price.
**ARS Pharmaceuticals Inc. (SPRY)**
ARS Pharma is a biopharmaceutical company developing needle-free treatments for severe allergic reactions.The company's investigational product, Neffy—a "no needle, no injection" solution for Type I allergic reactions or anaphylactic reactions—is currently under FDA review, with a decision expected by October 2, 2024. Neffy, marketed under the name EURneffy, is also being evaluated by the European Medicines Agency.
Last month, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended approval of EURneffy for the emergency treatment of allergic reactions (anaphylaxis). The final decision from the EMA is anticipated this quarter (Q3).
SPRY was highlighted on our platform on June 11, 2024, when it was trading at approximately $8.99. By the close of trading on Friday, it had risen to $11.35, reflecting a 26% increase over one month.
**Medpace Holdings Inc. (MEDP)**
Medpace is a global, full-service clinical contract research organization (CRO) that offers phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device sectors.
The company reported revenue of $511.0 million for Q1 2024, compared to $434.1 million in the corresponding quarter of the previous year.
In April, while disclosing its Q1 2024 results, Medpace forecasted full-year 2024 revenue to be in the range of $2.150 billion to $2.200 billion, representing growth of 14.0% to 16.7% over 2023 revenue of $1.886 billion.
The financial results for Q2 2024 are scheduled to be reported after market close on July 22, 2024.
We featured MEDP on our site on October 25, 2022, when it was trading at around $202.45, and again on April 24, 2024, when it was trading at around $415. On Friday, the stock closed at $443.
**Avidity Biosciences Inc. (RNA)**
Avidity focuses on creating a new class of RNA therapeutics known as Antibody Oligonucleotide Conjugates. The company has three clinical programs: Del-desiran for DM1, Del-brax for FSHD, and AOC 1044 for DMD44.
Del-desiran, formerly known as AOC 1001, is undergoing a phase III study for Myotonic Dystrophy Type 1, dubbed HARBOR. Del-brax, also known as AOC 1020, showed promising results in a phase I/II trial for facioscapulohumeral muscular dystrophy (FSHD), named FORTITUDE. AOC 1044 is currently being evaluated in a phase I/II trial for Duchenne Muscular Dystrophy amenable to exon 44 skipping, titled EXPLORE44, with data expected this quarter (Q3).
RNA was featured on our site on February 20, 2024, when it was trading at around $14.33. On Friday, the stock closed at $44.80, representing an impressive gain of over 200% in just five months.
**Revolution Medicines Inc. (RVMD)**
Revolution Medicines is a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers.
The company is set to provide an update on its RMC-6236 pancreatic ductal adenocarcinoma (PDAC) clinical development program on July 15, 2024. Initial data reported from a phase 1/1b trial of RMC-6236 as monotherapy for advanced solid tumors harboring KRASG12X mutations, last September, were promising.
RVMD was featured on our site on May 9, 2023, when it was trading at approximately $24.17. On Friday, the stock closed at $45.14, reflecting a gain of over 85% from our published price.
